Immune Suppression Therapy in Aplastic Anemia: Influencing Factors on Response and Survival
Jong Youl Jin, Dong Wook Kim, Jong Wook Lee, Chi Wha Han, Woo Sung Min, Chong Won Park, Chun Choo Kim, Dong Jip Kim, Hack Ki Kim, Hae Hiang Song
Korean J Intern Med. 1995;10(1):25-31. Published online 1995 Jan 1 DOI: https://doi.org/10.3904/kjim.1995.10.1.25
Citations to this article as recorded by 
Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study
Yingying Shen, Qi Liu, Hangchao Li, Wenbin Liu, Huijin Hu, Yuechao Zhao, Yuzhu Li, Ying Chen, Shan Liu, Qinghong Yu, Haifeng Zhuang, Liqiang Wu, Zhiping Hu, Zhiyin Zheng, Jianping Shen, Shenyun Lin, Yiping Shen, Yuhong Zhou, Baodong Ye, Dijiong Wu
Annals of Hematology.2023; 102(3): 503. CrossRef
Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study
Qi Liu, Huijie Dong, Yuzhu Li, Yingying Shen, Yilei Hong, Ying Chen, Shan Liu, Xiaolian Wu, Wenbin Liu, Huijin Hu, Yuechao Zhao, Shenyun Lin, Yiping Shen, Yuhong Zhou, Baodong Ye, Dijiong Wu
Lipids in Health and Disease.2022;[Epub] CrossRef
Clinical Response of Antilymphocyte Globulin-Based Treatment in Patients in Taiwan with Aplastic Anemia: Positive Hepatitis C Antibody May Represent a Response Predictor
Yin-Hsun Feng, Chia-Jui Yen, Wen-Tsung Huang, Wu-Chou Su, Tsai-Yun Chen, Chao-Jung Tsao
International Journal of Hematology.2004; 79(2): 133. CrossRef